iOncologi, Inc., a clinical-stage biopharmaceutical company, announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor-targeted immunotherapies. This strategic acquisition significantly enhances iOncologi’s capabilities in developing immunotherapies for solid tumors.

The acquisition aligns with iOncologi’s broader strategy to expand its therapeutic pipeline, leverage RNA-based immunotherapies, and drive innovation in oncology.

As part of the transaction, iOncologi, Inc. and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99% of TargImmune’s shares, warrants, and options.

Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure ensures the continuation of TargImmune’s research into tumor-targeted RNA therapies while benefiting from iOncologi’s resources and strategic vision.

“This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumors,” said Dr. Edgardo Rodriguez-Lebron, iOncologi’s recently appointed CEO. “TargImmune’s pioneering approaches perfectly align with our mission to develop transformative cancer therapies.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.